Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 6

Shared decision-making based on different features of risk in the context of diabetes mellitus and rheumatoid arthritis

Authors Monica Ortendahl

Published 15 January 2008 Volume 2007:3(6) Pages 1175—1180

Monica Ortendahl
Royal Institute of Technology, Stockholm, Sweden
Abstract: There is an increased awareness about patients’ involvement in the clinical decision process where uncertainty is an unavoidable condition. The impact of psychological factors like risk aversion, risk aversion and time, asymmetry in risk aversion, and risk and control on shared decision-making is discussed. In addition to differences in risk estimates, doctors and patients may exhibit a difference in perception of time perspectives, and losses versus gains.
A summary of valuation factors in shared decision-making is presented: (a) the doctors tend to follow expected value combinations more closely, while the patient is more risk aversive; (b) unwillingness to take risks increases for rare outcomes; (c) there is an increased tendency to take risks with delayed outcomes of the decisions; (d) the doctor is generally well informed about risk and time aspects for different diseases, whereas this might not always be the case with the patient; (e) rheumatoid arthritis and diabetes mellitus are chronic diseases, and both create a vulnerability to a variety of complications over time; (f) rheumatoid arthritis demands different combinations of treatments sequentially over time, whereas diabetes mellitus is treated with insulin; (g) many diseases, like rheumatoid arthritis and diabetes mellitus, are not completely affected by control, as the disease may constantly progress.
Keywords: shared, decision-making, risk, aversion, time, control

Download Article [PDF] 

Readers of this article also read:

In vitro study of novel gadolinium-loaded liposomes guided by GBI-10 aptamer for promising tumor targeting and tumor diagnosis by magnetic resonance imaging

Gu MJ, Li KF, Zhang LX, Wang H, Liu LS, Zheng ZZ, Han NY, Yang ZJ, Fan TY

International Journal of Nanomedicine 2015, 10:5187-5204

Published Date: 17 August 2015

Electrospun gelatin/polycaprolactone nanofibrous membranes combined with a coculture of bone marrow stromal cells and chondrocytes for cartilage engineering

He X, Feng B, Huang C, Wang H, Ge Y, Hu R, Yin M, Xu Z, Wang W, Fu W, Zheng J

International Journal of Nanomedicine 2015, 10:2089-2099

Published Date: 17 March 2015

Myelodysplastic disorders carrying both isolated del(5q) and JAK2V617F mutation: concise review, with focus on lenalidomide therapy

Musto P, Simeon V, Guariglia R, Bianchino G, Grieco V, Nozza F, La Rocca F, Marziano G, Lalinga AV, Fabiani E, Voso MT, Scaravaglio P, Mecucci C, D'Arena G

OncoTargets and Therapy 2014, 7:1043-1050

Published Date: 13 June 2014

Sigma-1 receptor concentration in plasma of patients with late-life depression: a preliminary study

Shimizu H, Takebayashi M, Tani M, Tanaka H, Yamagata B, Kurosawa K, Yamada H, Hachisu M, Hisaoka-Nakashima K, Okada-Tsuchioka M, Mimura M, Iwanami A

Neuropsychiatric Disease and Treatment 2013, 9:1867-1872

Published Date: 6 December 2013

Autoantibody profiling in systemic lupus erythematosus

Hsieh SC, Yu CL

Current Biomarker Findings 2013, 3:55-65

Published Date: 23 August 2013

ISVH – October Newsletter

Prof. Roland Asmar, David Oldfield

Vascular Health and Risk Management 2008, 4:1145-1146

Published Date: 10 October 2008

Clinical studies with oral lipid based formulations of poorly soluble compounds

Dimitrios G Fatouros, Ditte M Karpf, Flemming S Nielsen, Anette Mullertz

Therapeutics and Clinical Risk Management 2007, 3:591-604

Published Date: 15 September 2007

Dietary approaches that delay age-related diseases

Arthur V Everitt, Sarah N Hilmer, Jennie C Brand-Miller, Hamish A Jamieson, A Stewart Truswell, Anita P Sharma, Rebecca S Mason, Brian J Morris, David G Le Couteur

Clinical Interventions in Aging 2006, 1:11-31

Published Date: 15 March 2006